In November 2021, Novozymes acquired a majority stake in Synergia Life Sciences, a leading developer and manufacturer of vitamin K2 and probiotics.
With three production sites and customers across the world, Synergia is a leading player in the field of vitamin K2-7 and spore-forming probiotics. Vitamin K2-7 complements the Novozymes OneHealth portfolio, and the company will continue to offer natural vitamin K2 to B2B customers under the MenaquinGold® ingredient brand.
Ulrich Irgens, General Manager (VP) Novozymes OneHealth
“As someone who has long been in the supplement industry and witnessed how vitamin K2 has grown over the past decade, I am excited that we have managed to bring it into our Novozymes OneHealth portfolio. MenaquinGold® is a natural vitamin and good fit to Novozymes as it talks to some of our core capabilities, i.e., fermentation. The science around K2 suggests it can play a part in helping to reduce some of the health challenges that align with our Novozymes OneHealth strategy. Yes, it is still a niche vitamin. But, when an RDI is established, it will likely be a trigger point for mass-market adoption, and we’ll be ready.”
Dr Dilip Mehta, CEO of Synergia Life Sciences
“We recognized Novozymes OneHealth’s strong commitment to supplements as a strategic match for our values and technologies. Through combining our pioneering portfolios, of which MenaquinGold® is a key part, we will continue to expand our global footprint in a meaningful way. Our natural vitamin K2 gives more people access to improving their health status and overall well-being through its multiple, evidenced health benefits. Collectively, our energies and competencies can make this happen.”
Jeff Lind, US National Director B2B Sales, Novozymes OneHealth
“I have been intricately involved in the vitamin supplement industry for over three decades and can both personally and professionally vouch for the benefits of MenaquinGold®. I believe we’ve only seen the tip of the iceberg in terms of how K2 can benefit our well-being and I’m proud to be representing the world’s largest fermenter of vitamin K2, Novozymes OneHealth.”
By acquiring Synergia Life Sciences, Novozymes accelerates its position in human health and functional foods and bolsters its developing and manufacturing capabilities. Vitamin K2-7 will support growth in Novozymes’ BioHealth platform.